Switch theme
Sign up to access all valuation multiples
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
2013
422
LTM Revenue $11.7M
LTM EBITDA -$489M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Denali Therapeutics has a last 12-month revenue (LTM) of $11.7M and a last 12-month EBITDA of -$489M.
In the most recent fiscal year, Denali Therapeutics achieved revenue of n/a and an EBITDA of -$493M.
Denali Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Denali Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $11.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $11.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 99% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$489M | XXX | -$493M | XXX | XXX | XXX |
| EBITDA Margin | -4166% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$534M | XXX | -$502M | XXX | XXX | XXX |
| EBIT Margin | -4556% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$471M | XXX | -$423M | XXX | XXX | XXX |
| Net Margin | -4014% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Denali Therapeutics's stock price is $14.
Denali Therapeutics has current market cap of $2.0B, and EV of $1.3B.
See Denali Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $2.0B | XXX | XXX | XXX | XXX | $-2.81 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Denali Therapeutics has market cap of $2.0B and EV of $1.3B.
Denali Therapeutics's trades at 3.8x EV/Revenue multiple, and -2.6x EV/EBITDA.
Equity research analysts estimate Denali Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Denali Therapeutics has a P/E ratio of -4.3x.
See valuation multiples for Denali Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 107.2x | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | -2.6x | XXX | -2.6x | XXX | XXX | XXX |
| EV/EBIT | -2.4x | XXX | -2.5x | XXX | XXX | XXX |
| EV/Gross Profit | 107.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.3x | XXX | -4.8x | XXX | XXX | XXX |
| EV/FCF | -2.3x | XXX | -3.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDenali Therapeutics's last 12 month revenue growth is 467%
Denali Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.2M for the same period.
Denali Therapeutics's rule of 40 is 413% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Denali Therapeutics's rule of X is -2999% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Denali Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 467% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -4166% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 413% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -2999% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Denali Therapeutics acquired XXX companies to date.
Last acquisition by Denali Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Denali Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Denali Therapeutics founded? | Denali Therapeutics was founded in 2013. |
| Where is Denali Therapeutics headquartered? | Denali Therapeutics is headquartered in United States of America. |
| How many employees does Denali Therapeutics have? | As of today, Denali Therapeutics has 422 employees. |
| Who is the CEO of Denali Therapeutics? | Denali Therapeutics's CEO is Dr. Ryan J. Watts, PhD. |
| Is Denali Therapeutics publicy listed? | Yes, Denali Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Denali Therapeutics? | Denali Therapeutics trades under DNLI ticker. |
| When did Denali Therapeutics go public? | Denali Therapeutics went public in 2017. |
| Who are competitors of Denali Therapeutics? | Similar companies to Denali Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Denali Therapeutics? | Denali Therapeutics's current market cap is $2.0B |
| What is the current revenue of Denali Therapeutics? | Denali Therapeutics's last 12 months revenue is $11.7M. |
| What is the current revenue growth of Denali Therapeutics? | Denali Therapeutics revenue growth (NTM/LTM) is 467%. |
| What is the current EV/Revenue multiple of Denali Therapeutics? | Current revenue multiple of Denali Therapeutics is 107.2x. |
| Is Denali Therapeutics profitable? | Yes, Denali Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Denali Therapeutics? | Denali Therapeutics's last 12 months EBITDA is -$489M. |
| What is Denali Therapeutics's EBITDA margin? | Denali Therapeutics's last 12 months EBITDA margin is -4166%. |
| What is the current EV/EBITDA multiple of Denali Therapeutics? | Current EBITDA multiple of Denali Therapeutics is -2.6x. |
| What is the current FCF of Denali Therapeutics? | Denali Therapeutics's last 12 months FCF is -$555M. |
| What is Denali Therapeutics's FCF margin? | Denali Therapeutics's last 12 months FCF margin is -4730%. |
| What is the current EV/FCF multiple of Denali Therapeutics? | Current FCF multiple of Denali Therapeutics is -2.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
